Samsung BioLogics

Jan 22, 2025 | ph.investing.com | Samsung BioLogics

Samsung Biologics reports fourth quarter and fiscal year 2024 financial results Recorded Q4'24 consolidated revenue of KRW 1.26 trillion Recorded FY'24 consolidated revenue of KRW 4.55 trillion Poised for further growth with expanded capacity and new service offerings, /PRNewswire/ -- Samsung (KS:) Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced financial results for the fourth quarter and fiscal year 2024.

Jan 22, 2025 | wnct.com | Samsung BioLogics

Your Opt Out Preference Signal is HonoredYour PrivacyWhen you visit our website, we store cookies on your browser to collect information. The information collected might relate to you, your preferences or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. However, you can choose not to allow certain types of cookies, which may impact your experience of the site and the services we are able to offer.

Jan 20, 2025 | samsungbiologics.com | Samsung BioLogics

A quality mindset is the foundation for CDMOs to bring innovative solutions in time for clients. Working with people ingrained in such a mindset can support clients to appropriately leverage cutting-edge technologies, advanced platforms and facilities, and scalable bioreactors to complete true end-to-end drug development and manufacturing.

Jan 15, 2025 | emporiaindependentmessenger.com | Samsung BioLogics

- The company to mark new phase of growth at Bio Campus II with the opening of Plant 5 in April- Samsung Biologics to offer ADC services and invest in advanced development and manufacturing capabilities to better address clients' needskAmkDA2? 4=2DDlQ=686?5$A2?r=2DDQmx}rwt~}[ kDA2? 4=2DDlQI?\=@42E:@?Qm$@FE9 z@C62k^DA2?mk^DA2?m[ kDA2? 4=2DDlQ=686?5$A2?r=2DDQmkDA2?

Jan 15, 2025 | sentinelsource.com | Samsung BioLogics

- The company to mark new phase of growth at Bio Campus II with the opening of Plant 5 in April - Samsung Biologics to offer ADC services and invest in advanced development and manufacturing capabilities to better address clients' needs , /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced its latest business achievements and 2025 outlook at the 43rd J.P. Morgan Healthcare Conference, which was held in San...